SUBSCRIBE: Print / eNewsletter
Adherence to Quality Metrics Could Improve Head and Neck Cancer Survival
Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death.
Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.
Low-Dose ATLG Prevents GVHD in Pediatric Hematologic Malignancies
A lower dose of rabbit anti–T-lymphocyte globulin was superior to a higher dose in children with hematologic malignancies undergoing transplant from an unrelated donor.
Eribulin Fails to Improve Over Physician’s Choice in NSCLC
A phase III trial failed to demonstrate superiority of eribulin over treatment of physician’s choice in patients with heavily pretreated non–small-cell lung cancer.
Adherence to Distress Screening Protocols Lacking
Adherence to screening protocols at cancer centers resulted in fewer emergency department visits and hospitalizations in the 2-month period after the screening.
FDA Panel Backs Trastuzumab Biosimilar
The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer.
Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab.
FDA Clears Test to Help Diagnose, Identify Blood Cancer Type
The FDA has approved the marketing of a new lab test used with flow cytometry to aid in the detection of several types of hematologic malignancies.
FDA Approves Ipilimumab for Pediatric Melanoma
The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease.
Immediate Chemotherapy After TURBT Reduces NMIBC Recurrence Risk
An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non–muscle-invasive bladder cancer (NMIBC).